Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: No PR to Explain USPTO Developments

No PR to Explain USPTO Developments

posted on Nov 16, 2009 09:44AM

This is why the BOD is incompetent. A statement that would provide some understanding of the USPTO developments would have been proactive, allowing shareholder an opportunity to better understand ramifications of 336. Instead, the company is silent. A position that has been a hallmark of the BOD. This is not a surprise, but an affirmation of the management inability to confront the issues at hand.

Share
New Message
Please login to post a reply